On January 12, 2026, the Company's indirectly wholly-owned subsidiary, China Digital Health Group Limited, entered into a non-binding memorandum of understanding (MOU) with Bo Hui Biotechnology Co., Ltd. to initiate a strategic collaboration aimed at strengthening the businesses of both parties. According to the terms outlined in the MOU, the two entities intend to establish a joint venture company, which will assemble qualified medical and biotechnology teams to jointly promote clinical treatment operations within hospitals located in the Greater Bay Area. Bo Hui is a biotechnology company based in Taiwan, recognized for its advanced cell therapy technologies, cancer immunotherapy cell platforms, and clinical implementation capabilities. The Board of Directors believes that the execution of this MOU signifies a new phase in the Group's foray into the medical biotechnology sector and presents an opportunity for the Group to pursue diversified business development. Through this strategic partnership with Bo Hui, the Group will be able to leverage its established network and connections within the Greater Bay Area, thereby broadening its revenue base and enhancing its overall competitiveness. Given the aforementioned rationale and anticipated benefits, the Board is of the view that entering into the MOU aligns with the overall interests of the Company and its shareholders.